Novartis AG
Explore Novartis
Core profile pages, annual revenue records, and related research hubs for this company.
Leadership History
4 leaders · Full leadership timeline
Novartis AG is a public company listed on NYSE under ticker NVS. Novartis makes money by discovering, developing, manufacturing, and commercializing patented medicines across cardiovascular, renal and metabolic, immunology, neuroscience, and oncology markets.
Novartis makes money by discovering, developing, manufacturing, and commercializing patented medicines across cardiovascular, renal and metabolic, immunology, neuroscience, and oncology markets.
Chief Executive Officer
Narasimhan executed the strategic spin-off of the Sandoz generics division in October 2023, transforming Novartis into a pure-play innovative medicines company. He has also overseen a significant portfolio optimization, divesting non-core assets and acquiring late-stage biotechs like Chinook and MorphoSys to strengthen the pipeline.
Chief Financial Officer
Kirsch managed the financial aspects of the Sandoz spin-off and the company's capital allocation strategy, including the $10 billion share buyback program. He played a key role in maintaining the company's strong credit rating and investor confidence during the transition to a pure-play model.
Chief Scientific Officer
Tsai leads the company's global R&D organization, overseeing a $10.8 billion annual budget and a pipeline of over 200 clinical projects. He has been instrumental in advancing the radioligand therapy platform and expanding the company's presence in rare diseases and immunology.
Chief Digital and Technology Officer
Tansche is responsible for driving the company's digital transformation, including the use of artificial intelligence in drug discovery and the implementation of data analytics to optimize clinical trials and commercial operations.
The biggest risk is patent expiry pressure, price regulation, trial failure, and competition from generics, biosimilars, and rival branded therapies.